 Connection
Michael Birrer to Tamoxifen
This is a "connection" page, showing publications Michael Birrer has written about Tamoxifen.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.211 |
|
|
|
-
Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Apr; 141(1):43-8.
Score: 0.130
-
Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999 Oct 28; 18(44):6063-70.
Score: 0.042
-
Kim S, Brown PH, Birrer MJ. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor. Oncogene. 1996 Mar 07; 12(5):1043-53.
Score: 0.032
-
Mulshine JL, Birrer M, Treston AM, Scott F, Quinn K, Avis I, Cuttitta F. Growth factors and other targets for rational application as intervention agents. Adv Exp Med Biol. 1992; 320:81-8.
Score: 0.006
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|